Mediwhale, an AI health diagnostics company based in Seoul, raised $12M in Series A2 funding.

Korea Development Bank led the round, with contributions from Woori Venture Partners, IMM Investment, and Mirae Asset Securities.

The funds will further enhance AI algorithms, pursue FDA approval for Reti-CVD, expand globally, and develop kidney disease risk prediction products.

Founded in 2016 and led by CEO Kevin Choi, Mediwhale’s Reti-CVD scans retinas to predict cardiovascular risk, matching cardiac CT scan accuracy.

Reti-CVD secured private reimbursement in Korea by June 2023, being deployed in over 7,200 cases across 57 institutions by August 2024.